Cargando…
Current Challenges for IDO2 as Target in Cancer Immunotherapy
Immune checkpoint inhibitors have revolutionized the clinical approach of untreatable tumors and brought a breath of fresh air in cancer immunotherapy. However, the therapeutic effects of these drugs only cover a minority of patients and alternative immunotherapeutic targets are required. Metabolism...
Autores principales: | Mondanelli, Giada, Mandarano, Martina, Belladonna, Maria Laura, Suvieri, Chiara, Pelliccia, Cristina, Bellezza, Guido, Sidoni, Angelo, Carvalho, Agostinho, Grohmann, Ursula, Volpi, Claudia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097162/ https://www.ncbi.nlm.nih.gov/pubmed/33968089 http://dx.doi.org/10.3389/fimmu.2021.679953 |
Ejemplares similares
-
The catalytic inhibitor epacadostat can affect the non-enzymatic function of IDO1
por: Panfili, Eleonora, et al.
Publicado: (2023) -
Membrane Localization and Phosphorylation of Indoleamine 2,3-Dioxygenase 2 (IDO2) in A549 Human Lung Adenocarcinoma Cells: First Steps in Exploring Its Signaling Function
por: Suvieri, Chiara, et al.
Publicado: (2023) -
High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients
por: Ludovini, Vienna, et al.
Publicado: (2021) -
Forced IDO1 expression in dendritic cells restores immunoregulatory signalling in autoimmune diabetes
por: Pallotta, Maria Teresa, et al.
Publicado: (2014) -
Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool
por: Mandarano, Martina, et al.
Publicado: (2020)